$6.64
2.92% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US49372L1008
Symbol
KZR
Sector
Industry

Kezar Life Sciences Inc Stock price

$6.64
-0.76 10.27% 1M
+0.30 4.68% 6M
-2.83 29.91% YTD
-3.03 31.36% 1Y
-151.16 95.79% 3Y
-30.66 82.20% 5Y
-170.86 96.26% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.20 2.92%
ISIN
US49372L1008
Symbol
KZR
Sector
Industry

Key metrics

Market capitalization $48.45m
Enterprise Value $-83.03m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.09
P/B ratio (TTM) P/B ratio 0.36
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-95.96m
Free Cash Flow (TTM) Free Cash Flow $-76.39m
Cash position $148.39m
EPS (TTM) EPS $-13.15
P/E forward negative
Short interest 2.50%
Show more

Is Kezar Life Sciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Kezar Life Sciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Kezar Life Sciences Inc forecast:

2x Buy
33%
4x Hold
67%

Analyst Opinions

6 Analysts have issued a Kezar Life Sciences Inc forecast:

Buy
33%
Hold
67%

Financial data from Kezar Life Sciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 1.06 1.06
34% 34%
-
-1.06 -1.06
115% 115%
-
- Selling and Administrative Expenses 21 21
15% 15%
-
- Research and Development Expense 72 72
7% 7%
-
-95 -95
2% 2%
-
- Depreciation and Amortization 1.06 1.06
-
-
EBIT (Operating Income) EBIT -96 -96
1% 1%
-
Net Profit -96 -96
9% 9%
-

In millions USD.

Don't miss a Thing! We will send you all news about Kezar Life Sciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kezar Life Sciences Inc Stock News

Neutral
Business Wire
about 2 months ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a business update. “The team at Kezar has made great progress towards completing t...
Neutral
Business Wire
about 2 months ago
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Kezar Life Sciences, Inc. (Nasdaq: KZR) concerning the Company and its directors' and officers' possible violations of state laws. If you own Kezar Life Sciences stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respe...
Neutral
Business Wire
2 months ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of one-for-ten (the “Reverse Stock Split”). The Reverse Stock Sp...
More Kezar Life Sciences Inc News

Company Profile

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco, California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

Head office United States
CEO Christopher Kirk
Employees 58
Founded 2015
Website www.kezarlifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today